Contessa Selected by Centers for Medicare & Medicaid Services to Test Medicare Dementia Care Model
Guiding an Improved Dementia Experience (GUIDE) Model Aims to Increase Care Coordination, Support for Caregivers Guiding an Improved Dementia Experience (GUIDE) Model Aims to Increase Care Coordina...
AMED vs. USPH: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Outpatient and Home Healthcare sector might want to consider either Amedisys (AMED) or U.S. Physical Therapy (USPH). But which of these two stocks is m...
Amedisys (AMED) Q2 Earnings and Revenues Top Estimates
Amedisys (AMED) came out with quarterly earnings of $1.32 per share, beating the Zacks Consensus Estimate of $1.22 per share. This compares to earnings of $1.37 per share a year ago.
AMED or USPH: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Amedisys (AMED) and U.S. Physical Therapy (USPH). But which of these two companies is the best optio...
Why Amedisys (AMED) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Amedisys (AMED) Q1 Earnings Surpass Estimates, Margins Rise
Amedisys (AMED) tops on revenue and earnings estimates in the first quarter of fiscal 2024.
Compared to Estimates, Amedisys (AMED) Q1 Earnings: A Look at Key Metrics
The headline numbers for Amedisys (AMED) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street esti...
Amedisys (AMED) Q1 Earnings and Revenues Surpass Estimates
Amedisys (AMED) came out with quarterly earnings of $1.03 per share, beating the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $1 per share a year ago.
Here's Why Amedisys (AMED) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Amedisys (AMED) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Is Amedisys (AMED) Down 2.5% Since Last Earnings Report?
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock?
How Amedisys (AMED) Stock Stands Out in a Strong Industry
Amedisys (AMED) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Oregon's health authority reviewing UnitedHealth's acquisition of Amedisys
Amedisys said on Tuesday Oregon's health authority has started a review of UnitedHealth Group's $3.3 billion acquisition of the home health and hospice caregiver.
AMED vs. USPH: Which Stock Is the Better Value Option?
Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Amedisys (AMED) and U.S. Physical Therapy (USPH). But which of these two stocks offers value investo...
Amedisys (AMED) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Amedisys (AMED) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics co...
Related Companies